Back to Stakeholders
Education

Cybin

Canada
6 Trials

Cybin Inc. (founded 2019) is a Canadian clinical-stage biopharmaceutical company developing psychedelic-based therapeutics—now operating as Helus Pharma—focused on proprietary novel serotonergic agonists and deuterated psilocin analogs for mental health conditions.

Quick Facts

Type
biotech
Founded
2019
HQ
Canada
Website
Visit

Sponsored Trials

6
RecruitingIII

A Phase 3 Trial to Assess CYB003 in Major Depressive Disorder (EMBRACE)

Start Date
Compounds
Psilocybin, Placebo
RecruitingIII

Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND) (EXTEND)

Start Date
Compounds
Psilocybin
RecruitingIII

A Study of a Psilocybin Analog (CYB003) in Humans With Major Depressive Disorder (APPROACH)

Start Date
Compounds
Psilocybin, Placebo
Active not recruitingII

A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD) With Depressive Symptoms

Start Date
Compounds
DMT
WithdrawnII

Effect of SSRIs on Response to Psilocybin Therapy

Start Date
Compounds
Psilocybin
CompletedI, II

A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder

Start Date
Compounds
Psilocybin, Placebo